Eltanexor (KPT-8602): Next-Generation XPO1 Inhibitor Tran...

2025-09-25

Explore how Eltanexor (KPT-8602), a second-generation XPO1 inhibitor, is redefining cancer therapeutics by targeting the XPO1/CRM1 nuclear export pathway. This article uniquely examines its translational impact on acute myeloid leukemia, lymphoid malignancies, and Wnt/β-catenin signaling modulation.

Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO): Un...

2025-09-24

Explore how the Protease Inhibitor Cocktail EDTA-Free, 100X in DMSO revolutionizes protein extraction and protease activity regulation. Discover advanced insights into its mechanism, unique compatibility with phosphorylation analysis, and its pivotal role in emerging research on oocyte maturation and post-transcriptional regulation.

Diclofenac as a Non-Selective COX Inhibitor in Advanced I...

2025-09-23

Explore the pivotal role of Diclofenac, a non-selective COX inhibitor, in dissecting inflammation and pain signaling pathways using modern in vitro models. This article highlights its molecular characteristics and practical applications for anti-inflammatory drug research.

c-Myc tag Peptide: Mechanistic Insights for Cancer and Im...

2025-09-22

Explore the mechanistic applications of the c-Myc tag Peptide in cancer research and immunoassay development. This article reviews the peptide's role in transcription factor regulation, displacement of c-Myc-tagged fusion proteins, and its implications for studies on cell proliferation and apoptosis.

Anti-RNA Polymerases IIIIII Subunit ABC1 Rabbit Monoclonal A

2025-09-19

Eltanexor (

2025-09-19

Eltanexor (KPT-8602), a second-generation XPO1 inhibitor, offers a unique approach to cancer research by targeting nuclear export and modulating oncogenic signaling pathways, including Wnt/β-catenin. This article explores the mechanistic underpinnings and emerging applications of Eltanexor in hematological malignancies and colorectal cancer, highlighting its potential as a versatile tool in cancer therapeutics targeting nuclear export.

FT895

2025-09-19

Vardenafil HCl Trihydrate in PDE5 Inhibition: Proteoform-...

2025-09-18

Explore the advanced application of Vardenafil HCl Trihydrate as a potent and selective phosphodiesterase type 5 inhibitor in contemporary smooth muscle and proteoform research, emphasizing its role in elucidating cGMP signaling and minimizing off-target effects.

Ropivacaine HCl

2025-09-18

Anti-RPS3 Rabbit Monoclonal Antibody

2025-09-18

Granisetron HCl

2025-09-17

CMLD010509

2025-09-17

SB 205607 dihydrobromide

2025-09-16

CDK1-IN-2

2025-09-16

3,3-Dimethylglutaric acid

2025-09-15